Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
National Institutes of Health
Connectez-vous et complétez votre Funding Passport pour voir si vous êtes admissible — un verdict transparent, fondé sur des règles, pas une boîte noire.
Se connecterÀ propos de cette possibilité
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Documents requis
La source officielle n'indique pas de documents précis ici — vérifiez les exigences avant de postuler.
Source et traçabilité de vérification
- Source officielle
- U.S. Federal Government (Grants.gov) ↗
- Première collecte
- 20 novembre 2026
- Dernière vérification
- 20 novembre 2026
- Empreinte du contenu
527f382e82e39ff8…